Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04442022
Title A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Karyopharm Therapeutics Inc

diffuse large B-cell lymphoma

B-cell lymphoma


Cisplatin + Dexamethasone + Gemcitabine + Rituximab

Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Selinexor

Age Groups: senior | adult
Covered Countries USA | ITA | ESP | AUT

No variant requirements are available.